7.10

2.80% -0.225

Vir Biotechnology Inc (VIR)

Overview News Price History Option Chain Financials Why VIR Down? Discussions Forecast

Vir Biotechnology Inc stock is traded at $7.10, with a volume of 141.92K. It is down -2.80% in the last 24 hours and down -25.68% over the past month. Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.

Previous Close:

$7.325

Open:

$7.28

24h Volume:

141.92K

Relative Volume:

0.07

Market Cap:

$992.92M

Revenue:

$62.04M

Net Income/Loss:

$-533.34M

P/E Ratio:

-1.8112

EPS:

-3.92

Net Cash Flow:

$-473.07M

1W Performance:

-11.77%

1M Performance:

-25.68%

6M Performance:

-12.21%

1Y Performance:

-34.98%

1-Day Range:

$7.11

$7.38

1-Week Range:

$6.96

$8.22

52-Week Range:

$6.56

$14.45

Vir Biotechnology Inc Stock (VIR) Company Profile

Name

Vir Biotechnology Inc

Sector

Healthcare (1172)

Industry

Biotechnology (680)

Phone

415-906-4324

Address

1800 OWENS STREET, SAN FRANCISCO, CA

Employee

408

Twitter

@Vir_Biotech

Next Earnings Date

2024-10-31

Latest SEC Filings

VIR's Discussions on Twitter

Compare VIR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VIR Vir Biotechnology Inc	7.11	992.92M	62.04M	-533.34M	-473.07M	-3.92
VRTX Vertex Pharmaceuticals Inc	501.64	130.96B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	685.01	75.53B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	579.08	35.07B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	242.49	31.72B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	250.25	26.76B	3.32B	-860.46M	-1.04B	-8.32

Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-29-24	Downgrade	JP Morgan	Overweight → Neutral
Sep-08-23	Downgrade	BofA Securities	Buy → Neutral
Mar-06-23	Upgrade	JP Morgan	Neutral → Overweight
Feb-21-23	Upgrade	Goldman	Neutral → Buy
Jan-27-23	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Sep-14-22	Initiated	SVB Leerink	Outperform
Sep-09-22	Initiated	Morgan Stanley	Underweight
Mar-03-22	Upgrade	Robert W. Baird	Underperform → Neutral
Dec-21-21	Downgrade	Robert W. Baird	Neutral → Underperform
Oct-25-21	Upgrade	JP Morgan	Underweight → Neutral
Sep-22-21	Downgrade	Goldman	Buy → Neutral
Jun-04-21	Resumed	Robert W. Baird	Neutral
Jan-27-21	Downgrade	JP Morgan	Neutral → Underweight
Jan-20-21	Reiterated	H.C. Wainwright	Buy
Oct-05-20	Initiated	BofA Securities	Buy
Sep-14-20	Upgrade	Goldman	Neutral → Buy
Sep-11-20	Upgrade	JP Morgan	Underweight → Neutral
Aug-20-20	Initiated	Needham	Buy
Mar-19-20	Downgrade	JP Morgan	Neutral → Underweight
Mar-13-20	Downgrade	Goldman	Buy → Neutral
Feb-27-20	Downgrade	Robert W. Baird	Neutral → Underperform
Feb-04-20	Downgrade	JP Morgan	Overweight → Neutral
Nov-14-19	Initiated	Robert W. Baird	Neutral
Nov-05-19	Initiated	Barclays	Overweight
Nov-05-19	Initiated	Cowen	Outperform
Nov-05-19	Initiated	Goldman	Buy
Nov-05-19	Initiated	JP Morgan	Overweight

View All

Vir Biotechnology Inc Stock (VIR) Latest News

08:05 AM

Major Breakthrough: Vir Biotech Advances First-Ever US Treatment for Deadly Hepatitis Delta - StockTitan

08:05 AM

Mar 11, 2025

Insider Sell: Vicki Sato Sells Shares of Vir Biotechnology Inc (VIR) - GuruFocus.com

Mar 11, 2025

SBI Securities Co. Ltd. Invests $60,000 in Vir Biotechnology, Inc. (NASDAQ:VIR) - Defense World

Mar 11, 2025

Mar 05, 2025

Vir Biotechnology price target raised to $14 from $10 at JPMorgan - MSN

Mar 05, 2025

Principal Financial Group Inc. Has $3.28 Million Stake in Vir Biotechnology, Inc. (NASDAQ:VIR) - Defense World

Mar 05, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Purchased by New York State Common Retirement Fund - Defense World

Mar 05, 2025

Rhumbline Advisers Has $1.74 Million Stock Position in Vir Biotechnology, Inc. (NASDAQ:VIR) - Defense World

Mar 05, 2025

Mar 04, 2025

Vir Biotechnology: Catalysts Ahead In Hepatitis And Oncology (NASDAQ:VIR) - Seeking Alpha

Mar 04, 2025

Mar 03, 2025

Vir Biotechnology's (VIR) Buy Rating Reiterated at Needham & Company LLC - MarketBeat

Mar 03, 2025

What is HC Wainwright’s Forecast for VIR Q1 Earnings? - Defense World

Mar 03, 2025

Mar 02, 2025

(VIR) On The My Stocks Page - Stock Traders Daily

Mar 02, 2025

HC Wainwright Reaffirms “Buy” Rating for Vir Biotechnology (NASDAQ:VIR) - Defense World

Mar 02, 2025

Vir Biotechnology’s Strategic Advancements and Financial Health Justify Buy Rating - TipRanks

Mar 02, 2025

Vir Biotechnology (NASDAQ:VIR) Stock Price Expected to Rise, Barclays Analyst Says - Defense World

Mar 02, 2025

Mar 01, 2025

Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results - Yahoo Canada Finance

Mar 01, 2025

Feb 28, 2025

Vir Biotechnology EVP vanina de Verneuil sells $67,402 in stock By Investing.com - Investing.com Canada

Feb 27, 2025

Vir Biotechnology EVP vanina de Verneuil sells $67,402 in stock - Investing.com India

Feb 27, 2025

Vir Biotechnology, Inc. (NASDAQ:VIR) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 27, 2025

Promising Oncology Developments and Strong Financial Outlook Support Buy Rating for Vir Biotechnology - TipRanks

Feb 27, 2025

Vir Biotechnology’s Promising Pipeline and Strong Financial Position Justify Buy Rating - TipRanks

Feb 27, 2025

Vir Biotechnology: Balancing Long-term Potential with Near-term Uncertainty – A Hold Rating Analysis - TipRanks

Feb 27, 2025

Vir Biotechnology, Inc. SEC 10-K Report - TradingView

Feb 27, 2025